Φορτώνει......
Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
A recent subgroup analysis of the TRIBE trial suggested that FOLFOXIRI plus bevacizumab may be a preferred option for the first-line treatment of only right-sided metastatic colorectal cancer (mCRC), regardless of RAS or BRAF status. Our subanalysis of a phase II trial of the FOLFOXIRI triplet regim...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | World J Gastrointest Oncol |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Baishideng Publishing Group Inc
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6304303/ https://ncbi.nlm.nih.gov/pubmed/30595807 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v10.i12.528 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|